Artiva Biotherapeutics (ARTV) said its experimental alloimmune therapy for rheumatoid arthritis could become the first deep B-cell depleting product to enter the market since RINVOQ was approved in 2019, provided Phase III results align with current expectations.
CEO Fred spoke at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, outlining a pipeline built around the firm’s AlloNK platform. He noted that if efficacy and safety continue to look strong in the randomized controlled trial, Artiva could claim first-mover advantage in a therapeutic space that has seen no comparable deep B-cell depleting entry in seven years.
Phase II enrollment reached more than 70 patients by the end of April, with 95% treated in community practice settings rather than hospital sites—a marker Fred said demonstrates both operational feasibility and patient demand despite warnings around the background chemotherapy regimen of cyclophosphamide and fludarabine (Cy/Flu). Of those enrolled, 21 were presented at EULAR, with 13 having reached the six-month follow-up mark at the time of the presentation.
Fred cited an individual refractory case: a patient with over a decade of RA who had cycled through two or three prior biologic or targeted synthetic therapies and underwent 11 knee taps before joining the trial. As of the last April update, that patient had been off medication for 18 months and had resumed normal activities including riding a motorcycle.
On commercial endpoints, Artiva is targeting a median time to next treatment of 12 to 24 months. In the company’s oncology experience with the same platform, the median duration of response approached two years and remained unreached. For rheumatoid arthritis, Fred referenced RINVOQ’s development trajectory—more than 1,000 patients treated in development with an ACR50 response rate of roughly 45% to 46% in first-line patients—as a benchmark for the size of the addressable market.
Looking ahead, Artiva expects Phase III site activation and patient enrollment to begin before the end of 2024, alongside year-end data reporting on at least 20 patients with six months of follow-up, including at least 10 meeting stricter Phase III eligibility criteria. Top-line results from the pivotal Phase III trial are expected by the end of 2028. The company stated it has sufficient capital to operate through 2029.
Shares rose 291% over the past year to a market capitalization of approximately $532 million. The stock traded at $11.19 in closing and $11.30 after hours on September 9, 2026. Analyst price targets ranged from $23 to $41, and the stock’s beta was noted at 2.2.
Artiva faces competition from firms including Bristol Myers Squibb, Novartis, Kyverna, Adicet Bio, Nkarta, and AbbVie in the broader autoimmune and cell therapy space. Fred acknowledged that while the current target product profile addresses a significant unmet need, there will be opportunities to further optimize the therapy before launch.
